Rutgers: Oral Medication Is the Leading Choice for Multiple Sclerosis Treatment
July 13, 2023
July 13, 2023
NEW BRUNSWICK, New Jersey, July 13 (TNSjou) -- Rutgers University issued the following news:
The majority of individuals with multiple sclerosis (MS) treat the chronic and progressive neurological disorder with oral medications, likely because of many factors, including convenience, consumer advertising and approval by health insurers, according to Rutgers researchers.
"While two injectable therapies known as platform injectables, were once the mainstay of multiple . . .
The majority of individuals with multiple sclerosis (MS) treat the chronic and progressive neurological disorder with oral medications, likely because of many factors, including convenience, consumer advertising and approval by health insurers, according to Rutgers researchers.
"While two injectable therapies known as platform injectables, were once the mainstay of multiple . . .